[CAS NO. 1286279-29-5] BMS-813160
PRODUCTS SPECIFICATIONS [1286279-29-5]
DESCRIPTION [1286279-29-5]
Overview
| MDL | MFCD31540731 |
|---|---|
| Molecular Weight | 484.64 |
| Molecular Formula | C25H40N8O2 |
| SMILES | CC(N[C@H]1[C@@H](N2C([C@@H](NC3=NC=NC4=CC(C(C)(C)C)=NN43)CC2)=O)CC[C@@H](NC(C)(C)C)C1)=O |
1 Publications Citing Use of MCE
Summary
IC50 & Target
|
CCR5 3.6 nM (IC 50 ) |
CCR2 6.2 nM (IC 50 ) |
In Vitro
BMS-813160 binds with CCR2, CCR5, CCR1, CCR4 and CXCR2 with IC
50
s of 6.2 nM, 3.6 nM, ＞25 μM, ＞40 μM and ＞40 μM, respectively
[2]
.
BMS-813160 shows activities to CCR2 CTX, CCR2 CD11b, CCR5 CTX and CCR5 CD11b with IC
50
s of 0.8, 4.8, 1.1 and 5.7 nM, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BMS-813160 (10-160 mg/kg; p.o. twice a day for two days) inhibits the migration of inflammatory monocytes and macrophages in mouse thioglycollate-induced peritonitis model, and shows excellent oral bioavailability [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Human-CCR2 knock-in C57BL/6 male mice with thioglycollate injection [2] |
| Dosage: | 10, 50 and 160 mg/kg |
| Administration: | Oral gavage; 10-160 mg/kg twice a day; for two days |
| Result: | Dose-dependently reduced inflammatory monocyte and macrophage infiltration in the peritoneum. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01049165 | Bristol-Myers Squibb |
Accelerated Intimal Hyperplasia
|
February 2010 | Phase 1 |
| NCT02996110 | Bristol-Myers Squibb |
Advanced Cancer
|
February 2, 2017 | Phase 2 |
| NCT03496662 | Washington University School of Medicine|Bristol-Myers Squibb|The Foundation for Barnes-Jewish Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Pancreatic Ductal Adenocarcinoma
|
August 31, 2018 | Phase 1|Phase 2 |
| NCT03184870 | Bristol-Myers Squibb |
Colorectal Cancer|Pancreatic Cancer
|
August 8, 2017 | Phase 1|Phase 2 |
| NCT04123379 | Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb |
Non-small Cell Lung Cancer|Hepatocellular Carcinoma
|
March 19, 2020 | Phase 2 |
| NCT01752985 | Bristol-Myers Squibb |
Diabetic Kidney Disease
|
March 18, 2013 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 25 mg/mL ( 51.58 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0634 mL | 10.3169 mL | 20.6339 mL |
| 5 mM | 0.4127 mL | 2.0634 mL | 4.1268 mL |
| 10 mM | 0.2063 mL | 1.0317 mL | 2.0634 mL |
References
- [1] Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
- [2] Cherney RJ, et al. BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate. ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758.